Pfizer is committed to ensuring that the manufacturing, use and disposal of our products, including antibiotics, does not adversely affect human health or the environment. Core to this commitment is taking action to assess and reduce, as needed, the risk of antibiotics in wastewater from Pfizer and supplier manufacturing facilities
Responsible antibiotic manufacturing practices are part of Pfizer’s Pharmaceuticals in the Environment (PiE) Program. In 2018, our PiE program continued to focus on wastewaters from antibiotic manufacturing operations through the completion of environmental risk assessments. These assessments have been completed for all internal antibiotic manufacturing sites and all external suppliers in India and China; assessments are underway for all other antibiotic suppliers globally. As a result, Pfizer has enhanced, and continues to enhance, operational practices at both our own and supplier facilities. At some locations, further assessment, including sampling, is underway. In 2018, we also partnered with technical consultants to explore additional antibiotic wastewater treatment options. This year, Pfizer also continued our leading role as part of the Antimicrobial Resistance (AMR) Industry Alliance manufacturing group (the Alliance Manufacturing Group). In the infographic below, learn more about progress made in 2018 with respect to AMR Industry Alliance commitments.
For more information about our commitment to assess and reduce, as needed, the risk of antibiotics in wastewater from Pfizer and supplier manufacturing facilities, visit our 2018 Annual Review at www.pfizer.com/annual.
Tweet me: Responsibly manufacturing antibiotics is part of @Pfizer’s commitment to putting #PatientsAtOurCenter. Find out how manufacturing, sustainability, and antibiotics come together at Pfizer: www.pfizer.com/annual
KEYWORDS: Pfizer, reports, manufacturing, sustainability, antibiotics, Antimicrobial resistance, Responsibility, product innovation, Corporate Social Responsibility